NYSE · CIK 0000921114
ARMP Armata Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Jul 14, 2026.
Armata Pharmaceuticals, Inc. (ARMP) has 25 SEC Form 4 filings on file from 10 insiders, the latest filed on Jul 14, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Armata Pharmaceuticals, Inc., scored.
Transactions
Every row filed, 26 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Deborah Birx Chief Executive Officer | FTax withholding Common Stock | -14,041 | $4.26 | $60k | 198,417 | Jul 14, 2026 |
| Apr 24, 2026 | Daniel B. Gilmer director | AGrant or award Stock Options (Right to Buy)derivative | +51,280 | $0.00 | $0 | 51,280 | Apr 28, 2026 |
| Mar 14, 2026 | Deborah Birx Chief Executive Officer | FTax withholding Common Stock | -4,919 | $10.54 | $52k | 212,458 | Mar 17, 2026 |
| Mar 14, 2026 | Pierre Kyme Chief Business Officer | FTax withholding Common Stock | -1,030 | $10.54 | $11k | 9,461 | Mar 17, 2026 |
| Mar 9, 2026 | Jules Haimovitz director | AGrant or award Stock Options (Right to Buy)derivative | +25,640 | $0.00 | $0 | 25,640 | Mar 11, 2026 |
| Mar 9, 2026 | Sarah J. Schlesinger director | AGrant or award Stock Options (Right to Buy)derivative | +25,640 | $0.00 | $0 | 25,640 | Mar 11, 2026 |
| Mar 9, 2026 | Deborah Birx Chief Executive Officer | AGrant or award Stock Options (Right to Buy)derivative | +421,226 | $0.00 | $0 | 421,226 | Mar 11, 2026 |
| Mar 9, 2026 | Kostas D Odysseas director | AGrant or award Stock Options (Right to Buy)derivative | +25,640 | $0.00 | $0 | 25,640 | Mar 11, 2026 |
| Mar 9, 2026 | Todd C. Peterson director | AGrant or award Stock Options (Right to Buy)derivative | +25,640 | $0.00 | $0 | 25,640 | Mar 11, 2026 |
| Mar 9, 2026 | Joseph M Patti director | AGrant or award Stock Options (Right to Buy)derivative | +25,640 | $0.00 | $0 | 25,640 | Mar 11, 2026 |
| Mar 9, 2026 | David Duane House SVP, Finance, and PFO | AGrant or award Stock Options (Right to Buy)derivative | +109,885 | $0.00 | $0 | 109,885 | Mar 11, 2026 |
| Mar 9, 2026 | Pierre Kyme Chief Business Officer | AGrant or award Stock Options (Right to Buy)derivative | +183,142 | $0.00 | $0 | 183,142 | Mar 11, 2026 |
| Mar 9, 2026 | Robin Kramer director | AGrant or award Stock Options (Right to Buy)derivative | +25,640 | $0.00 | $0 | 25,640 | Mar 11, 2026 |
| Jul 10, 2025 | Deborah Birx Chief Executive Officer | FTax withholding Common Stock | -13,637 | $2.27 | $31k | 217,377 | Jul 14, 2025 |
| Mar 14, 2025 | Pierre Kyme Chief Business Officer | FTax withholding Common Stock | -1,027 | $1.95 | $2,003 | 10,491 | Apr 25, 2025 |
| Jul 10, 2024 | Deborah Birx Chief Executive Officer | FTax withholding Common Stock | -22,925 | $2.68 | $61k | 237,075 | Apr 25, 2025 |
| Mar 14, 2025 | Deborah Birx Chief Executive Officer | FTax withholding Common Stock | -6,061 | $1.95 | $12k | 231,014 | Apr 25, 2025 |
| Feb 5, 2025 | Deborah Birx Chief Executive Officer | AGrant or award Stock Options (Right to Buy)derivative | +240,000 | $0.00 | $0 | 240,000 | Feb 7, 2025 |
| Feb 5, 2025 | Jules Haimovitz director | AGrant or award Stock Options (Right to Buy)derivative | +54,343 | $0.00 | $0 | 54,343 | Feb 7, 2025 |
| Feb 5, 2025 | David Duane House SVP, Finance, and PFO | AGrant or award Stock Options (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Feb 7, 2025 |
| Feb 5, 2025 | Robin Kramer director | AGrant or award Stock Options (Right to Buy)derivative | +54,343 | $0.00 | $0 | 54,343 | Feb 7, 2025 |
| Feb 5, 2025 | Pierre Kyme Chief Business Officer | AGrant or award Stock Options (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 7, 2025 |
| Feb 5, 2025 | Joseph M Patti director | AGrant or award Stock Options (Right to Buy)derivative | +54,343 | $0.00 | $0 | 54,343 | Feb 7, 2025 |
| Feb 5, 2025 | Todd C. Peterson director | AGrant or award Stock Options (Right to Buy)derivative | +54,343 | $0.00 | $0 | 54,343 | Feb 7, 2025 |
| Feb 5, 2025 | Sarah J. Schlesinger director | AGrant or award Stock Options (Right to Buy)derivative | +54,343 | $0.00 | $0 | 54,343 | Feb 7, 2025 |
| Feb 5, 2025 | Kostas D Odysseas director | AGrant or award Stock Options (Right to Buy)derivative | +54,343 | $0.00 | $0 | 54,343 | Feb 7, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Deborah BirxChief Executive Officer
- Daniel B. Gilmerdirector
- Jules Haimovitzdirector
- David Duane HouseSVP, Finance, and PFO
- Robin Kramerofficer, director, cfo
- Pierre KymeChief Business Officer
- Kostas D Odysseasdirector
- Joseph M Pattidirector
- Todd C. Petersondirector
- Sarah J. Schlesingerdirector
Questions about ARMP
Answered from the filings on this page, as of the latest one.
Are insiders buying ARMP?
No. In the last 90 days no insider at Armata Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ARMP on the open market?
No open-market trade has been scored at Armata Pharmaceuticals, Inc.. The latest Form 4 on file was filed on Jul 14, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Armata Pharmaceuticals, Inc.?
10 people have filed a Form 4 at Armata Pharmaceuticals, Inc., among them Deborah Birx (Chief Executive Officer), Daniel B. Gilmer (director), Jules Haimovitz (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.